SARS-CoV-2 Pseudovirus, JN.1 variant

Comprehensive Neutralization Assay Solutions for Advancing COVID-19 Research

Get your pseudovirus

JN.1 variant Advantages

This pseudovirus is pseudotyped with the Spike Glycoprotein of SARS-CoV-2 virus, JN.1 variant (GISAID Accession Number: EPI_ISL_20393961). This pseudovirus carries a modified genome that expresses a luciferase reporter gene (GFP on request).

Up to 2,000 reactions per mL (96-well plate)

Get a signal-to-background ratio of ≥10³ with 0.5 µL per well

Infectious titer of at least 10⁵ RLU/µL

The transduction efficiency is evaluated using HEK293 ACE2⁺ cells.

Lot to lot functionally validated

Infectivity and neutralization are evaluated for each batch

Lead Time: 2 - 3 week

We provide you with freshly produced pseudoviruses

QC report Order Now

Features

Enable specific detection

Expression of Spike glycoprotein, from JN.1 variant, as the sole surface antigen

Enhanced safety

Our pseudoviruses use a 3rd-generation lentivirus core and must be handled in BSL-2 conditions

Characterization of thermal stability

Stable at least 6 month at -80 °C

Support high-throughput screening

QC report Order Now

Applications

Pseudoviruses provide a safe and versatile platform for SARS-CoV-2 virus research and the development of therapeutic countermeasures. SARS-CoV-2 pseudoviruses have several important applications in research and development, including:

Vaccine Development

They are used to test the efficacy of new vaccines by evaluating their ability to induce neutralizing immune responses without the need for live pathogenic viruses.

Neutralizing Monoclonal Antibody Screening

Pseudoviruses enable rapid and safe screening of monoclonal antibodies targeting specific strains of the SARS-CoV-2 virus.

Antiviral Resistance Studies

They help study viral mutations and evaluate how these mutations affect sensitivity to antiviral treatments.

Fundamental Research on Viral Entry

Pseudoviruses are used to understand the mechanisms of viral entry into host cells, which is crucial for developing new therapies targeting these processes.

Treatment Efficacy Testing

They allow for the quick assessment of new antiviral agents’ effectiveness in controlled environments without the risks associated with highly pathogenic viruses.

QR reports Order Now

B.1.1.7 (Alpha) Variant's Background

The SARS-CoV-2 Omicron variant JN.1 (a descendant lineage of BA.2.86) is a highly transmissible variant of interest first identified in 2023 and rapidly spread across multiple countries (WHO). JN.1 is characterized by several additional mutations in the spike protein compared with its parent lineage BA.2.86, including the L455S substitution, which is located in the receptor-binding domain and may affect immune recognition (CDC).

Compared with earlier Omicron sublineages, JN.1 demonstrates enhanced transmissibility and growth advantage, contributing to its rapid increase in prevalence globally during late 2023 and early 2024 (WHO; CDC). While current evidence does not indicate increased disease severity, JN.1 shows immune escape properties that may reduce neutralization by antibodies from prior infection or vaccination, although updated vaccines continue to provide protection against severe outcomes (WHO; CDC). These characteristics highlight the importance of continued genomic surveillance and vaccination strategies to monitor and mitigate the impact of emerging SARS-CoV-2 variants.

SARS-CoV-2 pseudovirus, JN.1 in Publications

The emergence and global spread of the SARS-CoV-2 JN.1 variant, characterized by increased transmissibility and partial immune escape, underscored the need for effective vaccines and antiviral strategies against evolving viral strains. By eliminating the need to handle infectious BSL-3 virus, pseudovirus neutralization assays offer a safe, rapid, scalable, and standardized platform for evaluating neutralizing monoclonal antibodies (mAbs) and antiviral compounds targeting the spike (S) protein of SARS-CoV-2 variants.

Neutralization escape, infectivity, and membrane fusion of JN.1-derived SARS-CoV-2 SLip, FLiRT, and KP.2 variants

 

Order Now

Documentation

Quality control reports

Access QR reports

SDS

Access SDS

×

Get your document

Fill out the form below to get your document

"*" indicates required fields

Name*

First Last

Email*

This field is hidden when viewing the form

Document URL